The 8th Floor

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Tuesday, November 7, 2023
Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additional notification thresholds, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Private, Option, Attention, Prospectus, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The ADSs (including the Additional ADSs) and Ordinary Shares offered in the Global Offering were offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Tuesday, November 7, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additive manufacturing file format, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Note, AMF, Private, Option, Attention, Prospectus, EU, Euronext

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).

Key Points: 
  • PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Pharmaceutical, Health, Varick Street, Capital market, Sale, Security (finance), Morgan Stanley, RBC Capital Markets, The 8th Floor, Inflammation, Telephone, Attention, Vesey Street, Equity capital markets, Bookrunner, SVB Securities, Alpine, RBC, Oppenheimer Holdings, 2nd Floor, Prospectus, TD, Autoimmunity, Lexington Avenue, Oppenheimer, State Street

The gross proceeds to Alpine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Alpine, are expected to be approximately $150.0 million.

Key Points: 
  • The gross proceeds to Alpine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Alpine, are expected to be approximately $150.0 million.
  • All shares of common stock to be sold in the offering are being sold by Alpine.
  • Morgan Stanley, TD Cowen and Leerink Partners are acting as joint book-running managers for the proposed public offering.
  • These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.

Crescent Point Announces CDN$500 Million Bought Deal Offering of Common Shares

Retrieved on: 
Monday, November 6, 2023
International Data Group, Sale, Capital, NYSE, CPG, RBC Capital Markets, BMO Capital Markets, The 8th Floor, Public expenditure, Telephone, News, Form, Acquisition, Attention, Vesey Street, Transaction, Offering, Risk, Prospectus, Indian stock exchange, Syndicate, ATTN:, Crescent, TSX, Crescent Point Energy, Life insurance, Security (finance)

CALGARY, Alberta, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Crescent Point Energy Corp. ("Crescent Point" or the "Company") (TSX and NYSE: CPG) today announced that it has entered into an agreement (the “Agreement”) with a syndicate of underwriters co-led by BMO Capital Markets and RBC Capital Markets (collectively the “Underwriters”) under which the Underwriters have agreed to purchase, on a bought deal basis 48,550,000 Crescent Point common shares (“Common Shares”) at $10.30 per Common Share for aggregate gross proceeds of approximately CDN$500 million (the “Offering”).

Key Points: 
  • CALGARY, Alberta, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Crescent Point Energy Corp. ("Crescent Point" or the "Company") (TSX and NYSE: CPG) today announced that it has entered into an agreement (the “Agreement”) with a syndicate of underwriters co-led by BMO Capital Markets and RBC Capital Markets (collectively the “Underwriters”) under which the Underwriters have agreed to purchase, on a bought deal basis 48,550,000 Crescent Point common shares (“Common Shares”) at $10.30 per Common Share for aggregate gross proceeds of approximately CDN$500 million (the “Offering”).
  • Crescent Point has also granted the Underwriters an over-allotment option (the “Over-Allotment Option”) to purchase, on the same terms and conditions of the Offering, up to an additional 15 percent of the Common Shares issued in connection with the Offering.
  • The maximum gross proceeds raised under the Offering will be approximately CDN$575 million, in the event the Over-Allotment Option is fully exercised.
  • FOR MORE INFORMATION ON CRESCENT POINT ENERGY, PLEASE CONTACT:
    Telephone: (403) 693-0020 Toll-free (US and Canada): 888-693-0020 Fax: (403) 693-0070
    Address: Crescent Point Energy Corp. Suite 2000, 585 - 8th Avenue S.W.

Lexeo Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, November 3, 2023
Suite, Sale, RBC Capital Markets, Montgomery Street, The 8th Floor, Telephone, Attention, State Street, Vesey Street, Equity capital markets, SVB Securities, Prospectus, Broadridge Financial Solutions, Therapy, Security (finance), Stifel

The gross proceeds to Lexeo from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Lexeo, are expected to be approximately $100.0 million.

Key Points: 
  • The gross proceeds to Lexeo from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Lexeo, are expected to be approximately $100.0 million.
  • In addition, Lexeo has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • All of the shares in the offering will be offered by Lexeo.
  • J.P. Morgan, Leerink Partners, Stifel and RBC Capital Markets are acting as joint book-running managers for the offering.

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Retrieved on: 
Thursday, November 2, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Code, Partnership, EIB, State Street, Guggenheim, Janssen, Tax, Guggenheim Partners, Qatar Investment Authority, Jefferies Group, Telephone, Form, Baillie Gifford, Cancer, Patient, Security (finance), The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, NBTXR3, ISIN, Private, Attention, Prospectus, Commercial code, Pharmaceutical industry, EU, Euronext

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.

Key Points: 
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023.
  • The expected use of proceeds represents the Company’s intentions based upon its current plans and business conditions.

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Retrieved on: 
Thursday, November 2, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Code, Partnership, EIB, State Street, Guggenheim, Janssen, Tax, Guggenheim Partners, Qatar Investment Authority, Jefferies Group, Telephone, Form, Baillie Gifford, Cancer, Patient, Security (finance), The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, Note, AMF, NBTXR3, ISIN, Private, Attention, Risk, Prospectus, Commercial code, Cryptocurrency, Pharmaceutical industry, EU, Euronext

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.

Key Points: 
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023.
  • The expected use of proceeds represents the Company’s intentions based upon its current plans and business conditions.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, Application, NANO, ADS, Madison Avenue, Note, AMF, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Risk, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

Alpine Immune Sciences Announces Proposed Public Offering

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Varick Street, Capital market, Sale, Security (finance), Morgan Stanley, RBC Capital Markets, The 8th Floor, Inflammation, Telephone, Attention, Vesey Street, Equity capital markets, Bookrunner, SVB Securities, Alpine, RBC, Oppenheimer Holdings, 2nd Floor, Prospectus, TD, Autoimmunity, Lexington Avenue, Oppenheimer, State Street

All shares of common stock to be sold in the proposed offering will be sold by Alpine.

Key Points: 
  • All shares of common stock to be sold in the proposed offering will be sold by Alpine.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Morgan Stanley, TD Cowen and Leerink Partners are acting as joint book-running managers for the proposed public offering.
  • RBC Capital Markets is acting as a bookrunner and Oppenheimer & Co. and H.C. Wainwright & Co. are acting as co-lead managers for the proposed public offering.